Literature DB >> 24184354

NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.

Rachel Rau1, Daniel Magoon2, Sarah Greenblatt2, Li Li2, Colleen Annesley3, Amy S Duffield4, David Huso5, Emily McIntyre2, John G Clohessy6, Markus Reschke6, Pier Paolo Pandolfi6, Donald Small3, Patrick Brown3.   

Abstract

Cytoplasmic nucleophosmin (NPMc(+)) mutations and FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations are two of the most common known molecular alterations in acute myeloid leukemia (AML); they frequently occur together, suggesting cooperative leukemogenesis. To explore the specific relationship between NPMc+ and FLT3/ITD in vivo, we crossed Flt3/ITD knock-in mice with transgenic NPMc+ mice. Mice with both mutations develop a transplantable leukemia of either myeloid or lymphoid lineage, definitively demonstrating cooperation between Flt3/ITD and NPMc+. In mice with myeloid leukemia, functionally significant loss of heterozygosity of the wild-type Flt3 allele is common, similar to what is observed in human FLT3/ITD+ AML, providing further in vivo evidence of the importance of loss of wild-type FLT3 in leukemic initiation and progression. Additionally, in vitro clonogenic assays reveal that the combination of Flt3/ITD and NPMc+ mutations causes a profound monocytic expansion, in excess of that seen with either mutation alone consistent with the predominance of myelomonocytic phenotype in human FLT3/ITD+/NPMc+ AML. This in vivo model of Flt3/ITD+/NPMc+ leukemia closely recapitulates human disease and will therefore serve as a tool for the investigation of the biology of this common disease entity.
Copyright © 2014 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24184354      PMCID: PMC3932758          DOI: 10.1016/j.exphem.2013.10.005

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  53 in total

1.  The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model.

Authors:  Ke Cheng; Paolo Sportoletti; Keisuke Ito; John G Clohessy; Julie Teruya-Feldstein; Jeffery L Kutok; Pier Paolo Pandolfi
Journal:  Blood       Date:  2009-08-07       Impact factor: 22.113

2.  Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

Authors:  Chunaram Choudhary; Christian Brandts; Joachim Schwable; Lara Tickenbrock; Bülent Sargin; Andrea Ueker; Frank-D Böhmer; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve
Journal:  Blood       Date:  2007-03-13       Impact factor: 22.113

Review 3.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.

Authors:  Brunangelo Falini; Ildo Nicoletti; Massimo F Martelli; Cristina Mecucci
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

4.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

Review 5.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

6.  Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.

Authors:  Paolo Sportoletti; Silvia Grisendi; Samia M Majid; Ke Cheng; John G Clohessy; Agnes Viale; Julie Teruya-Feldstein; Pier Paolo Pandolfi
Journal:  Blood       Date:  2008-01-22       Impact factor: 22.113

7.  The incidence and clinical significance of nucleophosmin mutations in childhood AML.

Authors:  Patrick Brown; Emily McIntyre; Rachel Rau; Soheil Meshinchi; Norman Lacayo; Gary Dahl; Todd A Alonzo; Myron Chang; Robert J Arceci; Donald Small
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

8.  Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis.

Authors:  Sina Koch; Angela Jacobi; Martin Ryser; Gerhard Ehninger; Christian Thiede
Journal:  Cells Tissues Organs       Date:  2008-02-27       Impact factor: 2.481

9.  Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.

Authors:  Li Li; Obdulio Piloto; Ho Bao Nguyen; Kathleen Greenberg; Kogo Takamiya; Frederick Racke; David Huso; Donald Small
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

10.  Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.

Authors:  I H I M Hollink; C M Zwaan; M Zimmermann; T C J M Arentsen-Peters; R Pieters; J Cloos; G J L Kaspers; S S N de Graaf; J Harbott; U Creutzig; D Reinhardt; M M van den Heuvel-Eibrink; C Thiede
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

View more
  17 in total

1.  Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.

Authors:  Lev M Kats; Markus Reschke; Riccardo Taulli; Olga Pozdnyakova; Kerri Burgess; Parul Bhargava; Kimberly Straley; Rahul Karnik; Alexander Meissner; Donald Small; Shinsan M Su; Katharine Yen; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Cell Stem Cell       Date:  2014-01-16       Impact factor: 24.633

Review 2.  The genomics of acute myeloid leukemia in children.

Authors:  Shannon E Conneely; Rachel E Rau
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

3.  NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia.

Authors:  Alina Rudorf; Tony Andreas Müller; Cathrin Klingeberg; Stefanie Kreutmair; Teresa Poggio; Sivahari Prasad Gorantla; Tamina Rückert; Annette Schmitt-Graeff; Anina Gengenbacher; Peter Paschka; Claudia Baldus; Robert Zeiser; George S Vassiliou; Allan Bradley; Justus Duyster; Anna Lena Illert
Journal:  Blood       Date:  2019-06-11       Impact factor: 22.113

4.  DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.

Authors:  Sara E Meyer; Tingting Qin; David E Muench; Kohei Masuda; Meenakshi Venkatasubramanian; Emily Orr; Lauren Suarez; Steven D Gore; Ruud Delwel; Elisabeth Paietta; Martin S Tallman; Hugo Fernandez; Ari Melnick; Michelle M Le Beau; Scott Kogan; Nathan Salomonis; Maria E Figueroa; H Leighton Grimes
Journal:  Cancer Discov       Date:  2016-03-25       Impact factor: 39.397

5.  Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.

Authors:  Yiting Lim; Lukasz Gondek; Li Li; Qiuju Wang; Hayley Ma; Haley Ma; Emily Chang; David L Huso; Sarah Foerster; Luigi Marchionni; Karen McGovern; David Neil Watkins; Craig D Peacock; Mark Levis; Bruce Douglas Smith; Akil A Merchant; Donald Small; William Matsui
Journal:  Sci Transl Med       Date:  2015-06-10       Impact factor: 17.956

Review 6.  Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.

Authors:  Yun Chen; Yihang Pan; Yao Guo; Wanke Zhao; Wanting Tina Ho; Jianlong Wang; Mingjiang Xu; Feng-Chun Yang; Zhizhuang Joe Zhao
Journal:  Stem Cell Investig       Date:  2017-06-02

Review 7.  Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Authors:  P Sportoletti; E Varasano; R Rossi; A Mupo; E Tiacci; G Vassiliou; M P Martelli; B Falini
Journal:  Leukemia       Date:  2014-09-02       Impact factor: 11.528

8.  FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.

Authors:  Ruiqi Zhu; Li Li; Bao Nguyen; Jaesung Seo; Min Wu; Tessa Seale; Mark Levis; Amy Duffield; Yu Hu; Donald Small
Journal:  Signal Transduct Target Ther       Date:  2021-05-24

Review 9.  The Biology and Targeting of FLT3 in Pediatric Leukemia.

Authors:  Colleen E Annesley; Patrick Brown
Journal:  Front Oncol       Date:  2014-09-23       Impact factor: 6.244

10.  Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations.

Authors:  Shaina N Porter; Andrew S Cluster; Wei Yang; Kelsey A Busken; Riddhi M Patel; Jiyeon Ryoo; Jeffrey A Magee
Journal:  Elife       Date:  2016-11-23       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.